Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-50520

Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

[img]Accepted Version
PDF - Registered users only
450kB

Abstract

VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:10 Nov 2011 14:13
Last Modified:29 Nov 2012 10:43
Publisher:American Academy of Neurology
ISSN:0028-3878
Publisher DOI:10.1212/WNL.0b013e31822f02e1
PubMed ID:21880994
Citations:Google Scholar™
Scopus®. Citation Count: 70

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page